Effect of early dexamethasone on major complications and all-cause mortality in severe burns (DEXA-BURN): study protocol for a multicenter, randomized, placebo-controlled, double-blind trial
Alexandre Bourdiol, Nicolas Bruder, François Dépret, Delphine Flattres, Laurent Flet, June Fortin, Anne-Emmanuelle Gaufichon, Boris Glavnik, Matthieu Jeanne, Alexandra Jobert, Boris Jung, Anne-Claire Lukaszewicz, Noéline Mathelier, Morgane Péré, Xavier Pichon, Hugues Ravaux, Pierre-Joachim Mahé, Karim Asehnoune, the DEXA-BURN study group · 2026
Read Effect of early dexamethasone on major complications and all-cause mortality in severe burns (DEXA-BURN): study protocol for a multicenter, randomized, placebo-controlled, double-blind trial by Alexandre Bourdiol, Nicolas Bruder, François Dépret, Delphine Flattres, Laurent Flet, June Fortin, Anne-Emmanuelle Gaufichon, Boris Glavnik, Matthieu Jeanne, Alexandra Jobert, Boris Jung, Anne-Claire Lukaszewicz, Noéline Mathelier, Morgane Péré, Xavier Pichon, Hugues Ravaux, Pierre-Joachim Mahé, Karim Asehnoune, the DEXA-BURN study group (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13548467.txt.
Description
Alexandre Bourdiol and a French study group laid out in 2026 the DEXA-BURN trial protocol, testing whether an early course of the steroid dexamethasone can cut major complications after severe burns. Badly burned patients suffer intense, lasting inflammation with frequent lung and kidney failure, yet no large trial has tested steroids in this group. The double-blind trial runs in ten French intensive care units.
Adults with burns over at least a fifth of the body who arrive within a day and need a ventilator will be randomized to five days of intravenous dexamethasone or a placebo. The main measure combines serious lung injury and kidney injury within 28 days, with deaths at 90 days tested next in a fixed sequence. Enrollment targets 478 patients, and side effects of steroids are tracked closely.
Catalog record
| CREATOR | Alexandre Bourdiol, Nicolas Bruder, François Dépret, Delphine Flattres, Laurent Flet, June Fortin, Anne-Emmanuelle Gaufichon, Boris Glavnik, Matthieu Jeanne, Alexandra Jobert, Boris Jung, Anne-Claire Lukaszewicz, Noéline Mathelier, Morgane Péré, Xavier Pichon, Hugues Ravaux, Pierre-Joachim Mahé, Karim Asehnoune, the DEXA-BURN study group |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 49483 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |